International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Department of Public Health, University Hospital Ghent, Ghent, Belgium.
Glob Heart. 2017 Dec;12(4):315-322.e3. doi: 10.1016/j.gheart.2015.11.003. Epub 2016 Mar 16.
The EUROASPIRE (European Action on Secondary and Primary Prevention by Intervention to Reduce Events) cross-sectional surveys describe time trends in lifestyle and risk factor control among coronary patients between 1999 and 2013 in Belgium, Czech Republic, Finland, France, Ireland, the Netherlands, Poland, Slovenia, and the United Kingdom as part of the EuroObservational Research Programme under the auspices of European Society of Cardiology.
This study sought to describe time trends in lifestyle, risk factor control, and the use of evidence-based medication in coronary patients across Europe.
The EUROASPIRE II (1999 to 2000), III (2006 to 2007), and IV (2012 to 13) surveys were conducted in the same geographical areas and selected hospitals in each country. Consecutive patients (≤70 years) after coronary artery bypass graft, percutaneous coronary intervention, or an acute coronary syndrome identified from hospital records were interviewed and examined ≥6 months later with standardized methods.
Of 12,775 identified coronary patients, 8,456 (66.2%) were interviewed. Proportion of current smokers was similar across the 3 surveys. Prevalence of obesity increased by 7%. The prevalence of raised blood pressure (≥140/90 mm Hg or ≥140/80 mm Hg with diabetes) dropped by 8% from EUROASPIRE III to IV, and therapeutic control of blood pressure improved with 55% of patients below target in IV. The prevalence of low-density lipoprotein cholesterol ≥2.5 mmol/l decreased by 44%. In EUROASPIRE IV, 75% were above the target low-density lipoprotein cholesterol <1.8 mmol/l. The prevalence of self-reported diabetes increased by 9%. The use of evidence-based medications increased between the EUROASPIRE II and III surveys, but did not change between the III and IV surveys.
Lifestyle habits have deteriorated over time with increases in obesity, central obesity, and diabetes and stagnating rates of persistent smoking. Although blood pressure and lipid management improved, they are still not optimally controlled and the use of evidence-based medications appears to have stalled apart from the increased use of high-intensity statins. These results underline the importance of offering coronary patients access to modern preventive cardiology programs.
作为欧洲心脏病学会欧洲观察性研究计划的一部分,EUROASPIRE(通过干预降低事件的二级和一级预防的欧洲行动)横断面调查描述了 1999 年至 2013 年期间,比利时、捷克共和国、芬兰、法国、爱尔兰、荷兰、波兰、斯洛文尼亚和英国的冠心病患者的生活方式和危险因素控制的时间趋势。
本研究旨在描述欧洲冠心病患者的生活方式、危险因素控制和循证药物使用的时间趋势。
EUROASPIRE II(1999 年至 2000 年)、III(2006 年至 2007 年)和 IV(2012 年至 13 年)调查在每个国家的相同地理区域和选定的医院进行。从医院记录中识别出经冠状动脉旁路移植术、经皮冠状动脉介入治疗或急性冠状动脉综合征的连续患者(≤70 岁),并在≥6 个月后使用标准化方法进行访谈和检查。
在 12775 名确定的冠心病患者中,有 8456 名(66.2%)接受了采访。三个调查中当前吸烟者的比例相似。肥胖的患病率增加了 7%。从 EUROASPIRE III 到 IV,血压升高(≥140/90mmHg 或≥140/80mmHg 伴糖尿病)的患病率下降了 8%,血压治疗控制得到改善,55%的患者血压低于目标值。低密度脂蛋白胆固醇≥2.5mmol/L 的患病率下降了 44%。在 EUROASPIRE IV 中,75%的患者低密度脂蛋白胆固醇<1.8mmol/L,超过目标值。自我报告的糖尿病患病率增加了 9%。循证药物的使用在 EUROASPIRE II 和 III 调查之间增加,但在 III 和 IV 调查之间没有变化。
随着肥胖、中心性肥胖和糖尿病的增加以及持续吸烟率的停滞不前,生活方式习惯已经恶化。尽管血压和血脂管理有所改善,但仍未得到最佳控制,除了高强度他汀类药物的使用增加外,循证药物的使用似乎已经停滞不前。这些结果强调了为冠心病患者提供现代预防心脏病学方案的重要性。